List view / Grid view
15 October 2014 | By Promethera Biosciences
HEP002 trial represents the world’s first Phase IIb/III trial with a stem cell-based medicinal product for the treatment of urea cycle disorders patients...
15 October 2014 | By Auspherix & Domainex
Domainex Ltd. and Auspherix Pty Ltd announced a collaboration that will progress Auspherix’s novel anti-infective drug discovery programme towards the nomination of a clinical candidate...
14 October 2014 | By GlobalData
The Netherlands’ pharmaceutical market value will rise slowly from approximately $6.7 billion in 2014 to $7.2 billion by 2020, with growth restricted by the government’s focus on generic drugs as a cost-containment tool, according to research and consulting firm GlobalData...
14 October 2014 | By Imaxio
Imaxio’s pro-immunogenic technology will be tested to enhance the efficacy of a candidate vaccine for the human papillomavirus (HPV)...
14 October 2014 | By Pharmalink
Pharmalink AB, a specialty pharma company focused on orphan and niche products, has elected Bengt Julander as Chairman of the Board of Directors...
14 October 2014 | By Janssen
Persistence of STELARA® (ustekinumab) significantly better than anti-TNFs in treatment of psoriasis according to observational study analysis...
14 October 2014 | By New Oncology
New Oncology announced that it has entered into a collaboration agreement with Gustave Roussy Cancer Campus, Paris...
14 October 2014 | By Rigontec GmbH
Rigontec GmbH, a privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of cancer and viral diseases, announces the first closing of its Series A financing round, raising €9.45 million...
14 October 2014 | By Cardio3 BioSciences
Cardio3 BioSciences announces it has received authorization from Swissmedic, the Swiss agency for the authorisation and supervision of therapeutic products, to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C-Cure® in Switzerland...
14 October 2014 | By Azbil BioVigilant
Azbil BioVigilant, inventors of Instantaneous Microbial Detection™, announced the introduction of its new IMD-W™ rapid microbial detection system for real-time water monitoring of pharmaceutical water sources...
13 October 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (NYSE:BMY), Pharmacyclics, Inc. (NASDAQ:PCYC), and Janssen Research & Development, LLC announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO® (nivolumab) in combination with IMBRUVICA® (ibrutinib), an oral Bruton's…
13 October 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company will host a teleconference on Friday, October 31, 2014, at 2:30 p.m. EDT (1:30 p.m. CDT) to review data presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology (CMSTO) in Chicago...
13 October 2014 | By Probiodrug AG
Probiodrug AG announces the launch of its Initial Public Offering and listing on Euronext Amsterdam...
13 October 2014 | By Evotec
Evotec AG announced that its multi-target collaboration with Bayer HealthCare has reached an important milestone for the transition of a molecule into pre-clinical development for the treatment of endometriosis...
13 October 2014 | By ABPI and OBN
The ABPI, which represents large, medium and small innovative research-based biopharmaceutical companies in the UK and OBN, the membership organisation that brings together the UK’s emerging life sciences companies, corporate partners and investors are delighted to announce their commitment to working together under a Memorandum of Understanding...
